businessbriefs
SubjectsAll subjects on briefs.cloud →
Saved
Strategy · Company stories

Philip Morris International

1987

PMI didn’t pivot to smoke-free—it built a regulatory firewall around Iqos while keeping cigarettes profitable.

Worth your time?3.5/5Yes.Study the whole thing.What works, what does not, who it is for ↓
11:24in productionCh. 1 · Not a startup, but a spinoff/ 11:24 · ceiling 15 min
5 chapters · 11:24Ceiling 15:00

The brief is written and checked. The video joins this page when it is cut.5 chapters · 1 min read · 11:24 planned

Read the brief

PMI is a tobacco company formed in 1987, spun off from Altria in 2008. It makes money selling cigarettes and smoke-free products globally. Its $12.5 billion R&D spend (99% on smoke-free) and $16 billion Swedish Match acquisition built a diversified nicotine portfolio—but only Iqos has FDA authorisation as a modified risk product. Its 1990 oil-for-cigarettes deal with the Soviet state shows how it prioritises market access over infrastructure. The gap between its ‘smoke-free future’ narrative and its continued reliance on combustible cigarettes remains unaddressed.

StrategyCompany storiesAddictionBrandingCapitalismAddiction across the network →
Chapters & takeaways5
  1. 1:15
    Not a startup, but a spinoff

    PMI was not founded in 1987—it was carved out of Altria in 2008, making its 'independence' a structural separation, not an origin story.

  2. 2:36
    R&D as redirection

    Its R&D is narrowly focused: $12.5 billion spent almost entirely on smoke-free products, anchored at a dedicated Swiss centre opened in 2009.

  3. 4:10
    Regulatory first, not technical first

    FDA authorisation for Iqos in 2020 was not a scientific endorsement—it was the first—and only—MRTP approval granted to any electronic cigarette alternative.

  4. 5:59
    Acquisition as acceleration

    The $16 billion Swedish Match deal bought Zyn and scale—not innovation—bolstering PMI’s pouch and oral nicotine position after Iqos had already gained regulatory traction.

  5. 7:42
    Barter before branding

    Its 1990 oil-for-cigarettes barter with the Soviet state shows how PMI entered volatile markets via commodity swaps—not branding or infrastructure.

2 more chaptersFewer chapters
Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • Using regulatory authorisation as a competitive moat
  • Deploying acquisitions to fill portfolio gaps post-R&D
  • Entering high-risk markets through commodity barter
What does not
  • PMI's smoke-free transition reduces its dependence on nicotine addiction.
  • Zyn or Veev have FDA authorisation as modified risk tobacco products.
  • PMI was founded in 1987 as an independent entity.
Study it if
  • Students of corporate strategy under regulatory constraint
  • Analysts tracking tobacco industry adaptation
  • Researchers studying FDA MRTP pathway effects
Skip it if
  • Those seeking evidence of public health leadership
  • Investors looking for pure-play smoke-free growth
  • Policy makers expecting industry self-regulation
Who should study it, and who should skipHide who it is for
The written brief1 min read

What the company or idea is

Philip Morris International is a tobacco company formed in 1987, legally headquartered in Stamford, Connecticut, and operationally based in Lausanne, Switzerland. It became independent from Altria in March 2008.

How it actually makes money

PMI makes money selling cigarettes and smoke-free products—including Iqos, Zyn, and Veev—primarily outside the United States. Its revenue shifted: Iqos surpassed Marlboro in net revenue by end-2023.

What works

Its $12.5 billion R&D spend (99% on smoke-free products, 2009–2023), the Neuchâtel R&D centre opened in 2009, and the $16 billion Swedish Match acquisition in 2022 collectively expanded its non-combustible portfolio and distribution reach.

What does not

Its smoke-free transition does not reduce its dependence on nicotine addiction. It retains cigarette sales as a core revenue stream while marketing alternatives as ‘reduced-risk’—a claim validated only for Iqos by the FDA, not for Zyn or Veev.

What to take from it

PMI’s strategy reveals how incumbents use regulatory pathways—not just innovation—to redefine markets. The FDA’s MRTP authorisation for Iqos created a commercial moat no competitor has yet matched.

Is it worth your time

Yes—if you are studying how legacy industries reposition themselves under regulatory and reputational pressure, using R&D spending, acquisitions, and regulatory authorisations as strategic levers.

Same desk · Strategy4 of 138
11:24
The Walt Disney CompanyWalt Disney · 1923The Walt Disney Company is an American multinational mass media and entertainment conglomerate founded on October 16, 1923, as the Disney Brothers Studio by Walt and Roy Disney in California. It rose to prominence in animation with Steamboat Willie (1928), diversified into live-action films, television, and theme parks in the 1950s, reversed a post-1966 decline under Michael Eisner via international theme park expansion and the Disney Renaissance (1989–1999), and transformed into a major entertainment conglomerate under Bob Iger through strategic acquisitions (Pixar, Marvel, Lucasfilm, 21st Century Fox). It operates the largest television and film studio in Hollywood.
13:07
Universal PicturesCarl Laemmle · 1912Universal Pictures was a business architecture designed to extract value from every layer of film — from performer contracts to theatre leases — using legal, spatial, and branding levers. Its success was tactical, not mythic.
11:01
The Coca-Cola CompanyAsa Griggs Candler · 1892The Coca-Cola Company was founded in 1892 by Asa Griggs Candler in Atlanta after he purchased the formula from John Stith Pemberton in 1888. It generated revenue by manufacturing and selling syrup to soda fountains, then licensing bottling rights for $1 per territory — a contract that transferred capital and operational risk to third parties while preserving brand control. By 1895 it achieved nationwide US distribution; exports began in 1899 (Cuba) and 1901 (Europe). Candler trademarked the brand and paid dividends in 1893, proving early financial viability. The model worked because it scaled without infrastructure — but failed to ensure product consistency across bottlers. This is a masterclass in leveraging intellectual property through contractual design, not product innovation.
12:12
Bernard Arnault1949Bernard Arnault is the chairman and CEO of LVMH — the world’s largest luxury goods company, formed in 1987 via merger of Louis Vuitton and Moët Hennessy. Under his leadership, LVMH expanded across fashion, jewellery, watches, and wine; became the largest company by market capitalisation in the eurozone (€313bn as of May 2021); and adopted a decentralised brand strategy that preserves brand heritage while consolidating financial control.
Up next in Business

Anglo American plc

1917 · 12:10

A century-old mining giant that cut 138,000 jobs in two years while rebranding as a green critical-minerals champion — with no evidence its new identity changes who pays or who bears the cost.

Next brief →Back to Strategy
12:10